Study wrapper · #1022
Therapeutic Potential of Incretin-Based Therapies for Alcohol Use Disorder - A narrative review of available clinical evidence.
Klausen MK, Fink-Jensen A Biological psychiatry. 2026.
DOI: 10.1016/j.biopsych.2026.07.010PubMed: 42486217
Editor's note
A narrative review synthesizing randomized, observational, and preclinical evidence on GLP-1 receptor agonists and alcohol use disorder. Only three randomized trials exist so far, and while observational data consistently point in the same direction, the authors are clear that larger long-term trials are still needed. Semaglutide is named as a leading candidate, though much of the evidence spans the drug class rather than one agent.
Plain-language abstract
This review summarizes evidence that GLP-1 receptor agonists, including semaglutide, are associated with reduced alcohol consumption and craving in people with alcohol use disorder. The strongest findings come from a small number of randomized trials plus larger observational datasets.
Related coverage
Mixed
Hunger pain and its reduction; qualitative insight from people with schizophrenia on semaglutide.
International journal of qualitative studies on health and well-beingn=——2026
Weak / none
Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting.
Journal of enzyme inhibition and medicinal chemistryn=——2026
Mixed
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
Journal of obstetrics and gynaecologyn=——2026